Skip to main content
Premium Trial:

Request an Annual Quote

Former ABI President Hunkapiller Surfaces at VC Shop Alloy Ventures

NEW YORK, Feb. 17 (GenomeWeb News) - Former Applied Biosystems president and founder Michael Hunkapiller has landed a job as general partner at private equity firm Alloy Ventures, the company said today.


Hunkapiller, who left ABI in August, will focus on what Alloy calls "the intersection of the firm's interests in information technology and life sciences innovations," and "in particular [on] technologies that will help realize the potential of large scale biology projects to fundamentally change the medical and biotechnology landscape."


The private-equity firm said Hunkapiller will invest in companies "that take a high technology approach to addressing important unmet clinical and research needs."


Based in Palo Alto, Calif., Alloy has invested in genomics-related tool companies such as ZyomyxAria Biosciences, and ABI.


Before his stint at ABI, which spanned 1998-2004, Hunkapiller was a senior research fellow at the California Institute of Technology, where he worked with Leroy Hood on the early development of several technologies that ABI would go on to sell. He received his PhD in chemical biology from Caltech in 1974.


Hunkapiller is at least the second high-profile ABI or Celera alumnus to leave Applera for VC shores. Chief Business Officer Peter Barrett left Celera in January 2002 for Atlas Ventures, where he leads the company's life science investment business.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.